Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 6:08 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 80 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Phosphate Buffered Saline Injection Clear all

Conditions: Moderate to Severe Convexity of Submental Fat, Safety, Efficacy
Interventions: Deoxycholic Acid, Placebo; Drug
Lead sponsor: Kythera Biopharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 93 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 8
States / cities: Newport Beach, California • San Francisco, California • West Hollywood, California + 5 more

Conditions: Carcinoma, Squamous Cell of Head and Neck, Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Carcinoma, Head And Neck
Interventions: Ficlatuzumab, Cetuximab; Drug
Lead sponsor: James J Lee; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 3
States / cities: Pittsburgh, Pennsylvania

Conditions: Hereditary Angioedema (HAE)
Interventions: ecallantide, Phosphate Buffer Saline (PBS),; Drug
Lead sponsor: Shire; Industry
Eligibility: 10 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Wheaton, Maryland

Conditions: Zika Virus, Zika Virus Infection, Virus Diseases, Flavivirus Infections, Flaviviral Diseases, Flaviviridae Infections, RNA Virus Infections
Interventions: VRC-ZKADNA090-00-VP, VRC-PBSPLA043-00-VP; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 15 Years to 35 Years
Enrollment: 2,428 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 3
States / cities: Miami, Florida • Edinburg, Texas • Houston, Texas

Conditions: Moderate or Severe Submental Fullness
Interventions: Deoxycholic Acid Injection, Placebo, Cold Compress, Lidocaine / Epinephrine, Loratadine, Ibuprofen, Compression Chin Strap; Drug · Other
Lead sponsor: Kythera Biopharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Stem Cell Transplantation, Ventricular Dysfunction, Left
Interventions: Autologous human mesenchymal cells (hMSCs), Autologous human bone marrow cells (hBMCs), Placebo; Biological
Lead sponsor: University of Miami; Other
Eligibility: 21 Years to 90 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Campylobacter Infection
Interventions: ALFQ, CJCV2; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Healthy Volunteers
Interventions: TDV, Placebo; Biological · Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Galveston, Texas • Seattle, Washington

Conditions: Dengue
Interventions: TDENV-PIV, TDENV-F17, Placebo; Biological · Other
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 39 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Syracuse, New York

Conditions: Brain Tumor, Glioblastoma, Medulloblastoma, Ependymoma, Anaplastic Astrocytoma
Interventions: Dendritic Cells, Imiquimod; Biological · Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Not listed
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Shigellosis
Interventions: Shigella4V2, Placebo; Biological
Lead sponsor: LimmaTech Biologics AG; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 97 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 3
States / cities: Atlanta, Georgia • Baltimore, Maryland • Cincinnati, Ohio

Conditions: Keratoconus, Keratoconus, Unstable
Interventions: Riboflavin 5'-Phosphate; Drug
Lead sponsor: Comprehensive EyeCare of Central Ohio; Other
Eligibility: 14 Years to 40 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Westerville, Ohio

Conditions: Critical Limb Ischemia
Interventions: Cord blood stem cell injection; Biological
Lead sponsor: Richard Burt, MD; Other
Eligibility: 18 Years to 72 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: PDR
Interventions: Macugen (Pegaptanib Sodium); Drug
Lead sponsor: Retina Institute of Hawaii; Other
Eligibility: Up to 75 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: HIV Infections
Interventions: VRC-HIVADV014-00-VP, VRC-HIVDNA009-00-VP, FFB, PBS; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 7
States / cities: Birmingham, Alabama • San Francisco, California • New York, New York + 3 more

Conditions: Osteoarthritis
Interventions: SM04690, Placebo; Drug
Lead sponsor: Biosplice Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 455 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 36
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 32 more

Conditions: HIV Infections
Interventions: AVX101, placebo; Biological · Other
Lead sponsor: AlphaVax, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2009
U.S. locations: 6
States / cities: Baltimore, Maryland • New York, New York • Rochester, New York + 2 more

Conditions: Herpes Simplex Type 2
Interventions: HerpV and QS-21, Placebo; Drug
Lead sponsor: Agenus Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 5
States / cities: Portland, Oregon • Houston, Texas • Seattle, Washington

Conditions: Osteoarthritis of the Knee
Interventions: 1.2% Sodium Hyaluronate, Buffered Saline; Device
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 596 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 34
States / cities: Homewood, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 30 more

Conditions: Low-Grade B-cell Lymphoma
Interventions: rhuFlt3L/CDX-301, Poly-ICLC; Drug
Lead sponsor: Joshua Brody; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Alzheimer Disease
Interventions: ACC-001 + QS-21, QS-21, Diluent: Phosphate Buffered Saline, ACC-001; Biological · Other
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 27
States / cities: Phoenix, Arizona • Sun City, Arizona • San Francisco, California + 11 more

Conditions: Wrinkles
Interventions: Elevess; Device
Lead sponsor: Anika Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 9
States / cities: Los Angeles, California • Boca Raton, Florida • Coral Gables, Florida + 6 more

Conditions: Hereditary Angioedema (HAE)
Interventions: ecallantide, Phosphate Buffer Saline (PBS), pH 7.0; Drug
Lead sponsor: Shire; Industry
Eligibility: 10 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 42
States / cities: Scottsdale, Arizona • Little Rock, Arkansas • Berkeley, California + 38 more

Conditions: Influenza
Interventions: VCL-IPM1, VCL-IPT1, PBS; Biological
Lead sponsor: Vical; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 3
States / cities: San Diego, California • Baltimore, Maryland • Stony Brook, New York

Search by objective public record fields.

Safety Study of ATX-101 (Deoxycholic Acid) in Subjects With Mild or Extreme Fullness of Submental Fat

Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioedema (HAE)

VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents

Patient Experience Study of Deoxycholic Acid Injection

The Transendocardial Autologous Cells (hMSC or hBMC) in Ischemic Heart Failure Trial (TAC-HFT)

Safety and Immunogenicity of CJCV2 With and Without ALFQ

Phase 1b Study Investigating Safety & Immunogenicity of TDV Given Intradermally by Needle or Needle-Free PharmaJet Injector

TDENV PIV and LAV Dengue Prime-boost Strategy Using AS03B Adjuvant

Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor

A Human Challenge Study to Assess Protection of a Shigella Tetravalent Bioconjugate Vaccine

Epi-On Corneal Crosslinking for Keratoconus

Efficacy and Safety of Umbilical Cord Blood Injection for Critical Limb Ischemia

A Single-Center Trial of Intravitreous Injections of Macugen (Pegaptanib Sodium) Given at Least 7 Days Before Vitrectomy Secondary To Tractional Retinal Detachment in Proliferative Diabetic Retinopathy

Safety of and Immune Response to Two Different HIV Vaccines, Each Followed by a Adenoviral Vaccine Boost, in HIV Uninfected Adults

A Study Evaluating the Safety, Tolerability, and Efficacy of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects

Safety of and Immune Response to an HIV-1 Subtype C Vaccine (AVX101) in HIV Uninfected Adults

Biological Efficacy Study of HerpV Vaccine With QS-21 to Treat Participants With Recurrent Genital Herpes

Investigation of 1.2% Sodium Hyaluronate for Treatment of Painful Chronic Osteoarthritis of the Knee

In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy

Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease

Safety Study of Cosmetic Tissue Augmentation in People of Color

Efficacy Study of DX-88 (Ecallantide) to Treat Acute Attacks of Hereditary Angioedema (HAE)

Pandemic Influenza Plasmid DNA Vaccines (Needle-Free)